Quibim Unveils Next-Generation Oncology Ecosystem Platform at RSNA 2025
New enhancements deliver advanced 3D visualization capabilities and an end-to-end prostate cancer management solution.
Chicago, IL, November 21, 2025 – Quibim, a global leader in medical imaging AI and quantitative imaging biomarkers, announced today the launch of its next-generation oncology ecosystem platform and will present it at the Radiological Society of North America (RSNA) 2025 Annual Meeting. This major product update positions QP-Prostate® as a comprehensive, end-to-end management workflow for prostate cancer care, supporting clinicians from the earliest stages of image acquisition through diagnosis, patient management and follow-up and sets the ground for the future release of QP-Breast in 2026.
Prostate cancer remains the second most common cancer among men worldwide, making early and accurate detection critical to improving survival rates and quality of life. Clinicians face growing challenges in delivering precise diagnostics while managing increasing patient volumes and complex imaging workflows. QP-Prostate® addresses these challenges by providing a fully integrated solution that combines advanced AI analytics, seamless clinical integration, and standardized reporting, covering the entire continuum of care.
The latest release brings a new level of intelligence and interactivity to prostate imaging. Introducing an upgraded user interface with advanced 3D visualization and editing tools that allow radiologists and urologists to explore prostate anatomy and lesions in greater detail, making biopsy targeting and planning more intuitive. The enhanced structured report, compliant with PI-RADS v2.1, automatically merges AI findings with radiologist annotations and clinical standards. Designed for seamless integration with PACS and electronic health record systems, these innovations strengthen QP-Prostate® as a comprehensive prostate ecosystem that reduces diagnostic uncertainty, enhances collaboration, and supports confident, data-driven decisions throughout the patient journey.
“The enhancements made to QP-Prostate® represent a fundamental advancement in how we approach prostate cancer management, and we are excited to launch this innovation into the U.S. market during RSNA,” said Nathan Clark, Chief Commercial Officer of Quibim. “QP-Prostate® has evolved into a fully integrated ecosystem, combining advanced 3D visualization with seamless workflow connectivity. By equipping healthcare providers with precision diagnostic tools across the whole process, we’re driving better precision diagnostics and improving patient outcomes across the entire lifecycle of care.”
Visit Quibim at RSNA Booth #4906 (South Hall) to experience live demonstrations of QP-Prostate’s latest capabilities.
Expanding Commercial Reach Through Strategic Channel Partnerships
Additionally, Quibim is pleased to announce its commercial expansion through a strategic partnership with Ferrum Health. In line with our commitment to excellence, Quibim has chosen to collaborate with Ferrum Health for our shared values and dedication to innovation and precision medicine. This carefully selected partnership not only strengthens Quibim’s mission but also accelerates its impact across the healthcare sector.
Ferrum Health’s AI Governance Suite enables secure, scalable deployment of QP-Prostate® within large health systems, ensuring rapid implementation and continuous performance monitoring across distributed imaging networks.
“Partnering with Quibim reflects Ferrum’s AI Governance mission. The complexity of deploying a highly precise, specialized AI solution like QP-Prostate® across enterprise health systems demands rigor, not just speed. The Ferrum platform ensures that Quibim’s algorithms are deployed securely, efficiently, scalably, and with continuous monitoring for drift and bias, which are non-negotiable in precision medicine. Going live in days not months allows health systems to immediately focus on using AI to improve patient care, not drown in IT help desk tickets,” says Elie Balesh, MD, radiologist and medical director for Ferrum Health.
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (United Kingdom), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. For more information, visit www.quibim.com.
About Ferrum
Ferrum Health connects AI insights across service lines, turning fragmented deployments into enterprise clinical intelligence. Our vendor-neutral suite validates and monitors clinical AI models within a health system’s owned, secure environment. Organizations use Ferrum to deploy models faster, validate performance objectively, and maintain complete visibility across their AI portfolio. Backed by $31 million in funding, including a Series A led by Foundry, serving over 500 care sites globally.